[go: up one dir, main page]

FI931169A7 - Parannetut rokotekoostumukset - Google Patents

Parannetut rokotekoostumukset Download PDF

Info

Publication number
FI931169A7
FI931169A7 FI931169A FI931169A FI931169A7 FI 931169 A7 FI931169 A7 FI 931169A7 FI 931169 A FI931169 A FI 931169A FI 931169 A FI931169 A FI 931169A FI 931169 A7 FI931169 A7 FI 931169A7
Authority
FI
Finland
Prior art keywords
vaccine formulations
improved vaccine
improved
formulations
vaccine
Prior art date
Application number
FI931169A
Other languages
English (en)
Swedish (sv)
Other versions
FI931169L (fi
FI931169A0 (fi
Inventor
Harold J Jennings
Christopher L Penney
Francis Michon
Original Assignee
North American Vaccine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North American Vaccine Inc filed Critical North American Vaccine Inc
Publication of FI931169A0 publication Critical patent/FI931169A0/fi
Publication of FI931169A7 publication Critical patent/FI931169A7/fi
Publication of FI931169L publication Critical patent/FI931169L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
FI931169A 1990-09-17 1991-09-12 Foerbaettrade vaccinkompositioner FI931169L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58337290A 1990-09-17 1990-09-17
PCT/CA1991/000326 WO1992004915A1 (en) 1990-09-17 1991-09-12 Improved vaccine compositions

Publications (3)

Publication Number Publication Date
FI931169A0 FI931169A0 (fi) 1993-03-16
FI931169A7 true FI931169A7 (fi) 1993-04-22
FI931169L FI931169L (fi) 1993-04-22

Family

ID=24332852

Family Applications (1)

Application Number Title Priority Date Filing Date
FI931169A FI931169L (fi) 1990-09-17 1991-09-12 Foerbaettrade vaccinkompositioner

Country Status (28)

Country Link
US (1) US5773007A (fi)
EP (1) EP0549617B1 (fi)
JP (1) JPH06500772A (fi)
CN (1) CN1060408A (fi)
AT (1) ATE135918T1 (fi)
AU (1) AU8441991A (fi)
BR (1) BR9106853A (fi)
CA (1) CA2090673A1 (fi)
CS (1) CS283991A3 (fi)
CZ (1) CZ42993A3 (fi)
DE (1) DE69118389T2 (fi)
DK (1) DK0549617T3 (fi)
ES (1) ES2084827T3 (fi)
FI (1) FI931169L (fi)
GR (1) GR3020117T3 (fi)
HR (1) HRP920874A2 (fi)
HU (1) HUT64237A (fi)
IE (1) IE913261A1 (fi)
IL (1) IL99403A0 (fi)
IS (1) IS3753A7 (fi)
MX (1) MX9101077A (fi)
NO (1) NO930938L (fi)
NZ (1) NZ239643A (fi)
OA (1) OA09776A (fi)
SK (1) SK18693A3 (fi)
WO (1) WO1992004915A1 (fi)
YU (1) YU153291A (fi)
ZA (1) ZA917356B (fi)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1008977A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5866132A (en) * 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
US5695768A (en) 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
EP1018877A4 (en) * 1995-10-17 2000-08-09 Dovetail Technologies Inc LOW MOLECULAR WEIGHT STIMULANTS OF BONE MARROW AND IMMUNE SYSTEM CELLS
JP2001508758A (ja) * 1996-02-01 2001-07-03 ノース・アメリカン・バクシーン・インコーポレイテッド グループｂナイセリア・メニンギチジス外膜（ｍｂ３）タンパク質の酵母からの発現およびワクチン
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
EP1051506B2 (en) 1997-12-23 2019-08-21 Pfizer Ireland Pharmaceuticals Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugates vaccines
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
BR9815953A (pt) * 1998-07-20 2001-03-06 Us Health Vacinas contra infecção provocada por escherichia coli o157
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US20080096236A1 (en) * 1998-08-25 2008-04-24 Binax, Inc. Method for Detecting the Presence of Target Bacteria or a Target Component Carbohydrate Antigen Thereof
US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
DE122009000054I1 (de) * 1999-03-19 2009-12-31 Glaxosmithkline Biolog Sa Impfstoff gegen bakterielle antigene
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
KR100947757B1 (ko) 2001-01-23 2010-03-18 아벤티스 파스퇴르 다가 수막구균 폴리사카라이드―단백질 접합체 백신
US20030035806A1 (en) * 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
US7534442B2 (en) * 2001-08-21 2009-05-19 The Brigham And Women's Hospital, Inc. Immunogenic compositions comprising covalently bound polysaccharides, antigen, and bacterial toxoid
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
PL378571A1 (pl) * 2003-02-01 2006-05-02 Neuralab Limited Czynna immunizacja dla wytworzenia przeciwciał przeciw rozpuszczalnemu A-ß
US9173931B2 (en) * 2003-08-06 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Process for preparing polysaccharide-protein conjugate vaccines
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
WO2007116409A2 (en) * 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
SI2182983T1 (sl) * 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
SG175092A1 (en) * 2009-04-14 2011-11-28 Novartis Ag Compositions for immunising against staphylococcus aerus
US8003112B2 (en) * 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
SG177310A1 (en) 2009-06-22 2012-02-28 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
CN102481352A (zh) 2009-06-22 2012-05-30 惠氏有限责任公司 金黄色葡萄球菌抗原的免疫原性组合物
WO2014033191A1 (en) * 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
CN102839159B (zh) * 2012-09-07 2014-03-19 江苏康淮生物科技有限公司 一种CoxA16病毒株和人用CoxA16灭活疫苗
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
CA3031797A1 (en) * 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
PL3678654T3 (pl) 2017-09-07 2024-12-16 Merck Sharp & Dohme Llc Polisacharydy pneumokokowe i ich zastosowanie w immunogennych koniugatach polisacharyd-białko nośnikowe
AU2019215216B2 (en) 2018-02-05 2025-04-17 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2019256218B2 (en) 2018-04-18 2025-10-16 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharides and immunogenic conjugate thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1138773A (en) * 1979-04-18 1983-01-04 George Wojcik Synthetic adjuvants for stimulation of antigenic responses
US4258029A (en) * 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US5019383A (en) * 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
EP0064366A1 (en) * 1981-04-29 1982-11-10 Beecham Group Plc Pharmaceutical compositions
US4663160A (en) * 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4639371A (en) * 1984-10-02 1987-01-27 New York Blood Center, Inc. Hepatitis B antigenic compositions and vaccines against hepatitis B derived therefrom
CA1267087A (en) * 1985-02-14 1990-03-27 Nicolaas Visser Synthetic immunogen
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
FR2581877B1 (fr) * 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
DK163176C (da) * 1985-09-27 1992-06-22 Schweiz Serum & Impfinst Ugiftig konjugatvaccine mod infektioner af pseudomonas aeruginosa- og escherichia coli- bakterier, fremgangsmaade til fremstilling heraf og anvendelse af vaccinen
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
ATE60999T1 (de) * 1986-12-19 1991-03-15 Duphar Int Res Dimethyldioctadecylammoniumbromid enthaltende stabilisierte adjuvanssuspension.
NZ223009A (en) * 1986-12-31 1990-06-26 Nl Rivm Of Thoven Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
EP0289110A3 (en) * 1987-02-02 1990-01-24 Swiss Serum and Vaccine Institute Berne Conjugate malaria vaccine
GB8807860D0 (en) * 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
EP0449958B9 (en) * 1988-12-19 2003-05-28 American Cyanamid Company Meningococcal class 1 outer-membrane protein vaccine

Also Published As

Publication number Publication date
EP0549617B1 (en) 1996-03-27
IE913261A1 (en) 1992-02-25
DK0549617T3 (da) 1996-04-22
US5773007A (en) 1998-06-30
ZA917356B (en) 1992-09-30
IS3753A7 (is) 1992-03-18
HRP920874A2 (en) 1996-04-30
CS283991A3 (en) 1992-04-15
NZ239643A (en) 1996-05-28
CA2090673A1 (en) 1992-03-18
NO930938D0 (no) 1993-03-16
JPH06500772A (ja) 1994-01-27
BR9106853A (pt) 1993-08-17
FI931169L (fi) 1993-04-22
AU8441991A (en) 1992-04-15
FI931169A0 (fi) 1993-03-16
HUT64237A (en) 1993-12-28
YU153291A (sh) 1994-06-24
HU9300746D0 (en) 1993-06-28
NO930938L (no) 1993-03-16
DE69118389D1 (de) 1996-05-02
EP0549617A1 (en) 1993-07-07
GR3020117T3 (en) 1996-08-31
MX9101077A (es) 1992-05-04
IL99403A0 (en) 1992-08-18
DE69118389T2 (de) 1996-08-29
ATE135918T1 (de) 1996-04-15
CZ42993A3 (en) 1994-04-13
SK18693A3 (en) 1993-08-11
WO1992004915A1 (en) 1992-04-02
CN1060408A (zh) 1992-04-22
OA09776A (en) 1993-11-30
ES2084827T3 (es) 1996-05-16

Similar Documents

Publication Publication Date Title
FI931169A7 (fi) Parannetut rokotekoostumukset
DE69126606D1 (de) Vakzine
FI931366A7 (fi) Parannettuja shampookoostumuksia
NO934009D0 (no) Farmasoeytiske formuleringer
NO930699D0 (no) Hoeyeffektiv vaeske/vaeske hydrosyklon
MX9203481A (es) Formulaciones.
MA22220A1 (fr) Formulations gelifiees
FI924669A7 (fi) Täidenvastaisia koostumuksia
KR900011476A (ko) 백신 제제
ATE156710T1 (de) Adjuvantien enthaltende impfstoffzusammensetzung
FI932320A7 (fi) Säädetysti vapauttavat koostumukset
DK0454735T3 (da) Vaccine sammensætning
FI925835A7 (fi) Liposomeja sisältävät rokotteet
FI944052L (fi) Oraalinen rokote
FI930577A0 (fi) Vaccin och behandlingsmetod foer hiv-infektion
FI925032A7 (fi) Rokotekoostumukset
BR9106516A (pt) Formulacoes pesticidas
FI924670A7 (fi) Täidenvastaisia koostumuksia
FI921141A7 (fi) Veteen dispergoituva geeliformulaatioita
ATE134386T1 (de) Vakzin-zusammensetzung
KR930702987A (ko) 구충활성제 배합물
ATA12390A (de) Artikulator
BR9106776A (pt) Formulacoes pesticidas
NO943251D0 (no) Oral vaksine
ID1028B (id) Vaksin